Anas Gazzah

7.9k total citations
99 papers, 2.1k citations indexed

About

Anas Gazzah is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Anas Gazzah has authored 99 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Oncology, 51 papers in Pulmonary and Respiratory Medicine and 26 papers in Molecular Biology. Recurrent topics in Anas Gazzah's work include Lung Cancer Treatments and Mutations (34 papers), Cancer Immunotherapy and Biomarkers (30 papers) and Cancer Genomics and Diagnostics (15 papers). Anas Gazzah is often cited by papers focused on Lung Cancer Treatments and Mutations (34 papers), Cancer Immunotherapy and Biomarkers (30 papers) and Cancer Genomics and Diagnostics (15 papers). Anas Gazzah collaborates with scholars based in France, Spain and United States. Anas Gazzah's co-authors include Jean‐Charles Soria, Benjamin Besse, David Planchard, Caroline Caramella, Aurélien Marabelle, Laura Mezquita, Christophe Massard, Antoine Hollebecque, Rastislav Bahleda and Andréa Varga and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Anas Gazzah

90 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anas Gazzah France 22 1.3k 861 553 355 305 99 2.1k
Tania Fleitas Spain 19 1.1k 0.9× 1.1k 1.2× 577 1.0× 570 1.6× 309 1.0× 58 2.3k
Esma Saâda-Bouzid France 23 1.4k 1.0× 951 1.1× 288 0.5× 240 0.7× 319 1.0× 88 2.0k
Wael A. Harb United States 23 1.4k 1.1× 759 0.9× 923 1.7× 423 1.2× 259 0.8× 118 2.5k
Lorenza Landi Italy 22 1.1k 0.9× 1.0k 1.2× 611 1.1× 423 1.2× 154 0.5× 85 1.8k
Vinod Ganju Australia 24 2.0k 1.5× 906 1.1× 655 1.2× 447 1.3× 144 0.5× 94 2.7k
Kimio Yonesaka Japan 25 2.2k 1.7× 1.2k 1.4× 789 1.4× 265 0.7× 304 1.0× 74 2.8k
María Alsina Spain 22 1.3k 1.0× 1.3k 1.5× 595 1.1× 286 0.8× 177 0.6× 109 2.5k
Andreas H. Marx Germany 26 1.3k 1.0× 822 1.0× 698 1.3× 301 0.8× 177 0.6× 75 2.2k
Yung‐Jue Bang South Korea 26 1.3k 1.0× 1.1k 1.2× 438 0.8× 216 0.6× 166 0.5× 72 2.0k
Yusri Elsayed United States 22 1.1k 0.8× 606 0.7× 1.1k 1.9× 208 0.6× 422 1.4× 51 2.4k

Countries citing papers authored by Anas Gazzah

Since Specialization
Citations

This map shows the geographic impact of Anas Gazzah's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anas Gazzah with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anas Gazzah more than expected).

Fields of papers citing papers by Anas Gazzah

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anas Gazzah. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anas Gazzah. The network helps show where Anas Gazzah may publish in the future.

Co-authorship network of co-authors of Anas Gazzah

This figure shows the co-authorship network connecting the top 25 collaborators of Anas Gazzah. A scholar is included among the top collaborators of Anas Gazzah based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anas Gazzah. Anas Gazzah is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gazzah, Anas, Nils Ternès, Joon Sang Lee, et al.. (2025). Biomarker analysis from a Phase 1/1b study of tusamitamab ravtansine in patients with advanced non-small cell lung cancer. Translational Oncology. 63. 102615–102615.
2.
Zullo, Lodovica, Maria‐Rosa Ghigna, Damien Vasseur, et al.. (2023). 80P Tumor microenvironment (TME) defines prognosis of EGFR-mutant non-small cell lung cancer (NSCLC). ESMO Open. 8(1). 101890–101890. 1 indexed citations
3.
Ghigna, Maria‐Rosa, Filippo Gustavo Dall’Olio, Martina Mandarano, et al.. (2023). 2356P The role of pathological features in predicting prognosis of patients with advanced RET-positive NSCLC. Annals of Oncology. 34. S1197–S1198. 1 indexed citations
4.
Smolenschi, Cristina, Antoine Hollebecque, Damien Vasseur, et al.. (2023). 1659P The use of liquid biopsy in patients with advanced pancreatic cancer (PDAC) to guide enrollment in phase I clinical trials. Annals of Oncology. 34. S913–S914. 1 indexed citations
5.
Tabernero, Josep, Philippe L. Bédard, Yung‐Jue Bang, et al.. (2023). Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens. Cancer Research Communications. 3(8). 1662–1671. 9 indexed citations
6.
Postel‐Vinay, Sophie, Matthieu Texier, Mihaela Aldea, et al.. (2023). Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial. British Journal of Cancer. 130(3). 417–424. 4 indexed citations
7.
Gazzah, Anas, Ratislav Bahleda, Antoine Hollebecque, et al.. (2023). Profile and outcome of cancer patients enrolled in contemporary phase I trials. European Journal of Cancer. 188. 1–7. 2 indexed citations
8.
Parisi, Claudia, Linda Mahjoubi, Anas Gazzah, & Fabrice Barlési. (2023). TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC). Cancer Treatment Reviews. 118. 102572–102572. 15 indexed citations
9.
Riudavets, Mariona, Damien Vasseur, Édouard Auclin, et al.. (2022). Clinical Utility and Outcomes Impact of Crystal Digital PCR of Sensitizing and Resistance EGFR Mutations in Patients With Advanced Non-Small Cell Lung Cancer. Clinical Lung Cancer. 23(6). e377–e383. 1 indexed citations
10.
Martín-Romano, Patricia, Léo Colmet‐Daage, Daphné Morel, et al.. (2022). Epigenetic gene alterations in metastatic solid tumours: results from the prospective precision medicine MOSCATO and MATCH-R trials. European Journal of Cancer. 173. 133–145. 1 indexed citations
11.
Aldea, Mihaela, Claudia Parisi, Luigi Cerbone, et al.. (2021). 1344P Molecular features of young cannabis smokers with advanced non-small cell lung cancer (aNSCLC). Annals of Oncology. 32. S1024–S1025. 3 indexed citations
12.
Mezquita, Laura, Caroline Rossoni, Édouard Auclin, et al.. (2021). Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non–small cell lung cancer treated with immunotherapy. European Journal of Cancer. 145. 221–229. 53 indexed citations
13.
Romano, P. Martin, Laura Mezquita, Ludovic Lacroix, et al.. (2020). 1930O Genomic alterations in solid tumours according to ESMO scale for clinical actionability of molecular targets (ESCAT). Annals of Oncology. 31. S1092–S1093. 5 indexed citations
14.
Sun, Roger, Stéphane Champiat, Jean‐Marie Michot, et al.. (2020). 1050P Does immunotherapy impact the outcomes of future anti-tumour therapies?. Annals of Oncology. 31. S718–S719. 1 indexed citations
15.
Gauci, Marie-Léa, Émilie Lanoy, Stéphane Champiat, et al.. (2018). Long-Term Survival in Patients Responding to Anti–PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation. Clinical Cancer Research. 25(3). 946–956. 106 indexed citations
16.
Mahjoubi, Linda, Franco Cecchi, Christophe Massard, et al.. (2018). Personalized therapy based on sequential molecular analysis leads to 30 months of survival in a patient with diffuse unresectable gastric linitis plastica. Tumori Journal. 104(6). NP38–NP41.
17.
Aspeslagh, Sandrine, Eduardo Castañón, Valérie Dyevre, et al.. (2018). Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours. European Journal of Cancer. 95. 68–74. 20 indexed citations
18.
Remón, Jordi, Caroline Caramella, Cécile Jovelet, et al.. (2017). Osimertinib benefit inEGFR-mutant NSCLC patients withT790M-mutation detected by circulating tumour DNA. Annals of Oncology. 28(4). 784–790. 133 indexed citations
19.
Lahmar, J., Laura Mezquita, Serge Koscielny, et al.. (2016). Immune checkpoint inhibitors (IC) induce paradoxical progression in a subset of non-small cell lung cancer (NSCLC). Annals of Oncology. 27. vi423–vi423. 12 indexed citations
20.
Bahleda, Rastislav, Antoine Hollebecque, Andréa Varga, et al.. (2015). Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours. British Journal of Cancer. 113(10). 1413–1420. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tania Fleitas Breakdown of academic impact, for papers by Esma Saâda-Bouzid Breakdown of academic impact, for papers by Wael A. Harb Breakdown of academic impact, for papers by Lorenza Landi Breakdown of academic impact, for papers by Vinod Ganju Breakdown of academic impact, for papers by Kimio Yonesaka Breakdown of academic impact, for papers by María Alsina Breakdown of academic impact, for papers by Andreas H. Marx Breakdown of academic impact, for papers by Yung‐Jue Bang Breakdown of academic impact, for papers by Yusri Elsayed
Rankless by CCL
2026